Product Collaborations

Affimed’s lead product candidates
are ready to enter clinical studies.

 
 
     
 
 

Product Collaborations

 
   
 
In September 2013, Affimed signed an agreement with the Leukemia and Lymphoma Society (LLS) in which LLS commits to co-funding of the phase 2 development of AFM13 of up to $4.4 million over 2 years. In doing so, the LLS recognized the critical need for safer and more durable therapies for HL. The LLS is committed to advancing breakthrough therapies, particularly for patients with unmet medical needs, and Affimed’s immunotherapy is emerging as a promising therapeutic option for HL patients. The LLS is the world’s largest voluntary health agency dedicated to blood cancer; its mission is: cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.   breakthrough therapies, particularly for patients with unmet medical needs, and Affimed’s immunotherapy is emerging as a promising therapeutic option for HL patients. The LLS is the world’s largest voluntary health agency dedicated to blood cancer; its mission is: cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
 
     
     
 



 
  Impressum Disclaimer